J Clin Oncol:基于乳腺X线检查的乳腺癌风险预测人工智能模型

2021-11-18 Nebula MedSci原创

乳腺癌在全球女性癌症中的发病率为24.2%,位居女性癌症的首位,其中52.9%发生在发展中国家

据2018年国际癌症研究机构(IARC)调查的最新数据显示,乳腺癌在全球女性癌症中的发病率为24.2%,位居女性癌症的首位,其中52.9%发生在发展中国家。准确的风险评估对于乳腺癌人群筛查项目的成功至关重要。具有高度敏感性和特异性的模型将使项目能够针对高危人群进行更精细的筛查,同时尽量减少对其他人群的过度医疗。

基于人工智能 (AI) 的风险模型已获得证明,与目前临床实践中使用的风险模型相比,有了显著的进步。但是,新人工智能的负责任部署还需要在不同人群中进行仔细验证。为此,Adam Yala等研究人员在全球不同筛查人群中验证了其人工智能模型——Mirai。

研究人员收集了不同地区的筛查性乳腺X线照片和病理证实的乳腺癌结果,评估了Uno对Mirai的一致性指数,以预测乳腺X光检查后1至5年内的乳腺癌风险。

Mirai在部分测试集中选择高危队列时的受试者工作曲线

共收集了来自全球7个地点的62185位个体的128793张乳腺X线照片,其中3815位个体在后来的5年内被确诊乳腺癌。Mirai在7家医院获得的一致性指数分别是0.75 (95% CI, 0.72-0.78)、0.75 (95%CI, 0.70-0.80)、0.77 (95%CI, 0.75-0.79)、0.77 (95%CI, 0.73-0.81)、0.81 (95%CI, 0.79-0.82)、0.79 (95% CI, 0.76-0.83) 和 0.84 (95% CI, 0.81-0.88)。

总结,Mirai是一种基于乳腺X光检查的风险模型,它在全球5个国家的7家医院的各种测试集中均保持了较高的准确性。这是迄今为止对基于人工智能的乳腺癌模型最广泛的验证,表明该技术可以广泛地改善乳腺癌的诊疗

原始出处:

Adam Yala, et al. Multi-Institutional Validation of a Mammography-Based Breast Cancer Risk Model. Journal of Clinical Oncology. November 12, 2021. https://ascopubs.org/doi/full/10.1200/JCO.21.01337

版权声明:
本网站所有内容来源注明为“williamhill asia 医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于williamhill asia 医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“williamhill asia 医学”。其它来源的文章系转载文章,或“williamhill asia 号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与williamhill asia 联系,williamhill asia 将立即进行删除处理。
在此留言
评论区 (6)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1866358, encodeId=8fee18663583c, content=<a href='/topic/show?id=16ce133504e' target=_blank style='color:#2F92EE;'>#Oncol#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=74, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13350, encryptionId=16ce133504e, topicName=Oncol)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b63894, createdName=minlingfeng, createdTime=Sun Jul 17 01:01:34 CST 2022, time=2022-07-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2062052, encodeId=b170206205213, content=<a href='/topic/show?id=e6e1e15509f' target=_blank style='color:#2F92EE;'>#癌风险#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=77, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71550, encryptionId=e6e1e15509f, topicName=癌风险)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d58a435, createdName=sjq027, createdTime=Tue May 10 15:01:34 CST 2022, time=2022-05-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1770344, encodeId=0eb81e70344c3, content=<a href='/topic/show?id=df9c23e868a' target=_blank style='color:#2F92EE;'>#乳腺癌风险#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=67, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=23786, encryptionId=df9c23e868a, topicName=乳腺癌风险)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=4a9538161180, createdName=gaoxiaoe, createdTime=Mon Oct 17 00:01:34 CST 2022, time=2022-10-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1298060, encodeId=4ed41298060b9, content=<a href='/topic/show?id=c42d18892ad' target=_blank style='color:#2F92EE;'>#X线#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=80, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=18892, encryptionId=c42d18892ad, topicName=X线)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=5c64275, createdName=piaojinhua, createdTime=Sat Nov 20 11:01:34 CST 2021, time=2021-11-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1485998, encodeId=17c4148599850, content=<a href='/topic/show?id=2c62100911a3' target=_blank style='color:#2F92EE;'>#风险预测#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=71, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=100911, encryptionId=2c62100911a3, topicName=风险预测)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e31a8064712, createdName=12498ebem21暂无昵称, createdTime=Sat Nov 20 11:01:34 CST 2021, time=2021-11-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1071663, encodeId=080b10e166334, content=<a href='/topic/show?id=73c423e2572' target=_blank style='color:#2F92EE;'>#乳腺癌#</a>风险预测<a href='/topic/show?id=d3a024808e0' target=_blank style='color:#2F92EE;'>#人工智能#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=216, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=23725, encryptionId=73c423e2572, topicName=乳腺癌), TopicDto(id=24808, encryptionId=d3a024808e0, topicName=人工智能)], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20211210/ede9c51184aa4f54ae6c1164cfb8eeac/967dbf3eff2943c7bf3ccfec3a776ab0.JPG, createdBy=a33789389, createdName=病毒猎手, createdTime=Fri Nov 19 09:53:56 CST 2021, time=2021-11-19, status=1, ipAttribution=)]
    2022-07-17 minlingfeng
  2. [GetPortalCommentsPageByObjectIdResponse(id=1866358, encodeId=8fee18663583c, content=<a href='/topic/show?id=16ce133504e' target=_blank style='color:#2F92EE;'>#Oncol#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=74, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13350, encryptionId=16ce133504e, topicName=Oncol)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b63894, createdName=minlingfeng, createdTime=Sun Jul 17 01:01:34 CST 2022, time=2022-07-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2062052, encodeId=b170206205213, content=<a href='/topic/show?id=e6e1e15509f' target=_blank style='color:#2F92EE;'>#癌风险#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=77, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71550, encryptionId=e6e1e15509f, topicName=癌风险)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d58a435, createdName=sjq027, createdTime=Tue May 10 15:01:34 CST 2022, time=2022-05-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1770344, encodeId=0eb81e70344c3, content=<a href='/topic/show?id=df9c23e868a' target=_blank style='color:#2F92EE;'>#乳腺癌风险#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=67, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=23786, encryptionId=df9c23e868a, topicName=乳腺癌风险)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=4a9538161180, createdName=gaoxiaoe, createdTime=Mon Oct 17 00:01:34 CST 2022, time=2022-10-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1298060, encodeId=4ed41298060b9, content=<a href='/topic/show?id=c42d18892ad' target=_blank style='color:#2F92EE;'>#X线#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=80, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=18892, encryptionId=c42d18892ad, topicName=X线)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=5c64275, createdName=piaojinhua, createdTime=Sat Nov 20 11:01:34 CST 2021, time=2021-11-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1485998, encodeId=17c4148599850, content=<a href='/topic/show?id=2c62100911a3' target=_blank style='color:#2F92EE;'>#风险预测#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=71, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=100911, encryptionId=2c62100911a3, topicName=风险预测)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e31a8064712, createdName=12498ebem21暂无昵称, createdTime=Sat Nov 20 11:01:34 CST 2021, time=2021-11-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1071663, encodeId=080b10e166334, content=<a href='/topic/show?id=73c423e2572' target=_blank style='color:#2F92EE;'>#乳腺癌#</a>风险预测<a href='/topic/show?id=d3a024808e0' target=_blank style='color:#2F92EE;'>#人工智能#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=216, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=23725, encryptionId=73c423e2572, topicName=乳腺癌), TopicDto(id=24808, encryptionId=d3a024808e0, topicName=人工智能)], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20211210/ede9c51184aa4f54ae6c1164cfb8eeac/967dbf3eff2943c7bf3ccfec3a776ab0.JPG, createdBy=a33789389, createdName=病毒猎手, createdTime=Fri Nov 19 09:53:56 CST 2021, time=2021-11-19, status=1, ipAttribution=)]
    2022-05-10 sjq027
  3. [GetPortalCommentsPageByObjectIdResponse(id=1866358, encodeId=8fee18663583c, content=<a href='/topic/show?id=16ce133504e' target=_blank style='color:#2F92EE;'>#Oncol#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=74, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13350, encryptionId=16ce133504e, topicName=Oncol)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b63894, createdName=minlingfeng, createdTime=Sun Jul 17 01:01:34 CST 2022, time=2022-07-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2062052, encodeId=b170206205213, content=<a href='/topic/show?id=e6e1e15509f' target=_blank style='color:#2F92EE;'>#癌风险#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=77, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71550, encryptionId=e6e1e15509f, topicName=癌风险)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d58a435, createdName=sjq027, createdTime=Tue May 10 15:01:34 CST 2022, time=2022-05-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1770344, encodeId=0eb81e70344c3, content=<a href='/topic/show?id=df9c23e868a' target=_blank style='color:#2F92EE;'>#乳腺癌风险#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=67, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=23786, encryptionId=df9c23e868a, topicName=乳腺癌风险)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=4a9538161180, createdName=gaoxiaoe, createdTime=Mon Oct 17 00:01:34 CST 2022, time=2022-10-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1298060, encodeId=4ed41298060b9, content=<a href='/topic/show?id=c42d18892ad' target=_blank style='color:#2F92EE;'>#X线#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=80, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=18892, encryptionId=c42d18892ad, topicName=X线)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=5c64275, createdName=piaojinhua, createdTime=Sat Nov 20 11:01:34 CST 2021, time=2021-11-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1485998, encodeId=17c4148599850, content=<a href='/topic/show?id=2c62100911a3' target=_blank style='color:#2F92EE;'>#风险预测#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=71, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=100911, encryptionId=2c62100911a3, topicName=风险预测)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e31a8064712, createdName=12498ebem21暂无昵称, createdTime=Sat Nov 20 11:01:34 CST 2021, time=2021-11-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1071663, encodeId=080b10e166334, content=<a href='/topic/show?id=73c423e2572' target=_blank style='color:#2F92EE;'>#乳腺癌#</a>风险预测<a href='/topic/show?id=d3a024808e0' target=_blank style='color:#2F92EE;'>#人工智能#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=216, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=23725, encryptionId=73c423e2572, topicName=乳腺癌), TopicDto(id=24808, encryptionId=d3a024808e0, topicName=人工智能)], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20211210/ede9c51184aa4f54ae6c1164cfb8eeac/967dbf3eff2943c7bf3ccfec3a776ab0.JPG, createdBy=a33789389, createdName=病毒猎手, createdTime=Fri Nov 19 09:53:56 CST 2021, time=2021-11-19, status=1, ipAttribution=)]
  4. [GetPortalCommentsPageByObjectIdResponse(id=1866358, encodeId=8fee18663583c, content=<a href='/topic/show?id=16ce133504e' target=_blank style='color:#2F92EE;'>#Oncol#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=74, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13350, encryptionId=16ce133504e, topicName=Oncol)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b63894, createdName=minlingfeng, createdTime=Sun Jul 17 01:01:34 CST 2022, time=2022-07-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2062052, encodeId=b170206205213, content=<a href='/topic/show?id=e6e1e15509f' target=_blank style='color:#2F92EE;'>#癌风险#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=77, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71550, encryptionId=e6e1e15509f, topicName=癌风险)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d58a435, createdName=sjq027, createdTime=Tue May 10 15:01:34 CST 2022, time=2022-05-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1770344, encodeId=0eb81e70344c3, content=<a href='/topic/show?id=df9c23e868a' target=_blank style='color:#2F92EE;'>#乳腺癌风险#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=67, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=23786, encryptionId=df9c23e868a, topicName=乳腺癌风险)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=4a9538161180, createdName=gaoxiaoe, createdTime=Mon Oct 17 00:01:34 CST 2022, time=2022-10-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1298060, encodeId=4ed41298060b9, content=<a href='/topic/show?id=c42d18892ad' target=_blank style='color:#2F92EE;'>#X线#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=80, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=18892, encryptionId=c42d18892ad, topicName=X线)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=5c64275, createdName=piaojinhua, createdTime=Sat Nov 20 11:01:34 CST 2021, time=2021-11-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1485998, encodeId=17c4148599850, content=<a href='/topic/show?id=2c62100911a3' target=_blank style='color:#2F92EE;'>#风险预测#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=71, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=100911, encryptionId=2c62100911a3, topicName=风险预测)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e31a8064712, createdName=12498ebem21暂无昵称, createdTime=Sat Nov 20 11:01:34 CST 2021, time=2021-11-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1071663, encodeId=080b10e166334, content=<a href='/topic/show?id=73c423e2572' target=_blank style='color:#2F92EE;'>#乳腺癌#</a>风险预测<a href='/topic/show?id=d3a024808e0' target=_blank style='color:#2F92EE;'>#人工智能#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=216, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=23725, encryptionId=73c423e2572, topicName=乳腺癌), TopicDto(id=24808, encryptionId=d3a024808e0, topicName=人工智能)], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20211210/ede9c51184aa4f54ae6c1164cfb8eeac/967dbf3eff2943c7bf3ccfec3a776ab0.JPG, createdBy=a33789389, createdName=病毒猎手, createdTime=Fri Nov 19 09:53:56 CST 2021, time=2021-11-19, status=1, ipAttribution=)]
    2021-11-20 piaojinhua
  5. [GetPortalCommentsPageByObjectIdResponse(id=1866358, encodeId=8fee18663583c, content=<a href='/topic/show?id=16ce133504e' target=_blank style='color:#2F92EE;'>#Oncol#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=74, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13350, encryptionId=16ce133504e, topicName=Oncol)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b63894, createdName=minlingfeng, createdTime=Sun Jul 17 01:01:34 CST 2022, time=2022-07-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2062052, encodeId=b170206205213, content=<a href='/topic/show?id=e6e1e15509f' target=_blank style='color:#2F92EE;'>#癌风险#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=77, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71550, encryptionId=e6e1e15509f, topicName=癌风险)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d58a435, createdName=sjq027, createdTime=Tue May 10 15:01:34 CST 2022, time=2022-05-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1770344, encodeId=0eb81e70344c3, content=<a href='/topic/show?id=df9c23e868a' target=_blank style='color:#2F92EE;'>#乳腺癌风险#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=67, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=23786, encryptionId=df9c23e868a, topicName=乳腺癌风险)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=4a9538161180, createdName=gaoxiaoe, createdTime=Mon Oct 17 00:01:34 CST 2022, time=2022-10-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1298060, encodeId=4ed41298060b9, content=<a href='/topic/show?id=c42d18892ad' target=_blank style='color:#2F92EE;'>#X线#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=80, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=18892, encryptionId=c42d18892ad, topicName=X线)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=5c64275, createdName=piaojinhua, createdTime=Sat Nov 20 11:01:34 CST 2021, time=2021-11-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1485998, encodeId=17c4148599850, content=<a href='/topic/show?id=2c62100911a3' target=_blank style='color:#2F92EE;'>#风险预测#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=71, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=100911, encryptionId=2c62100911a3, topicName=风险预测)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e31a8064712, createdName=12498ebem21暂无昵称, createdTime=Sat Nov 20 11:01:34 CST 2021, time=2021-11-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1071663, encodeId=080b10e166334, content=<a href='/topic/show?id=73c423e2572' target=_blank style='color:#2F92EE;'>#乳腺癌#</a>风险预测<a href='/topic/show?id=d3a024808e0' target=_blank style='color:#2F92EE;'>#人工智能#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=216, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=23725, encryptionId=73c423e2572, topicName=乳腺癌), TopicDto(id=24808, encryptionId=d3a024808e0, topicName=人工智能)], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20211210/ede9c51184aa4f54ae6c1164cfb8eeac/967dbf3eff2943c7bf3ccfec3a776ab0.JPG, createdBy=a33789389, createdName=病毒猎手, createdTime=Fri Nov 19 09:53:56 CST 2021, time=2021-11-19, status=1, ipAttribution=)]
  6. [GetPortalCommentsPageByObjectIdResponse(id=1866358, encodeId=8fee18663583c, content=<a href='/topic/show?id=16ce133504e' target=_blank style='color:#2F92EE;'>#Oncol#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=74, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13350, encryptionId=16ce133504e, topicName=Oncol)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b63894, createdName=minlingfeng, createdTime=Sun Jul 17 01:01:34 CST 2022, time=2022-07-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2062052, encodeId=b170206205213, content=<a href='/topic/show?id=e6e1e15509f' target=_blank style='color:#2F92EE;'>#癌风险#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=77, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71550, encryptionId=e6e1e15509f, topicName=癌风险)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d58a435, createdName=sjq027, createdTime=Tue May 10 15:01:34 CST 2022, time=2022-05-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1770344, encodeId=0eb81e70344c3, content=<a href='/topic/show?id=df9c23e868a' target=_blank style='color:#2F92EE;'>#乳腺癌风险#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=67, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=23786, encryptionId=df9c23e868a, topicName=乳腺癌风险)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=4a9538161180, createdName=gaoxiaoe, createdTime=Mon Oct 17 00:01:34 CST 2022, time=2022-10-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1298060, encodeId=4ed41298060b9, content=<a href='/topic/show?id=c42d18892ad' target=_blank style='color:#2F92EE;'>#X线#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=80, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=18892, encryptionId=c42d18892ad, topicName=X线)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=5c64275, createdName=piaojinhua, createdTime=Sat Nov 20 11:01:34 CST 2021, time=2021-11-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1485998, encodeId=17c4148599850, content=<a href='/topic/show?id=2c62100911a3' target=_blank style='color:#2F92EE;'>#风险预测#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=71, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=100911, encryptionId=2c62100911a3, topicName=风险预测)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e31a8064712, createdName=12498ebem21暂无昵称, createdTime=Sat Nov 20 11:01:34 CST 2021, time=2021-11-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1071663, encodeId=080b10e166334, content=<a href='/topic/show?id=73c423e2572' target=_blank style='color:#2F92EE;'>#乳腺癌#</a>风险预测<a href='/topic/show?id=d3a024808e0' target=_blank style='color:#2F92EE;'>#人工智能#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=216, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=23725, encryptionId=73c423e2572, topicName=乳腺癌), TopicDto(id=24808, encryptionId=d3a024808e0, topicName=人工智能)], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20211210/ede9c51184aa4f54ae6c1164cfb8eeac/967dbf3eff2943c7bf3ccfec3a776ab0.JPG, createdBy=a33789389, createdName=病毒猎手, createdTime=Fri Nov 19 09:53:56 CST 2021, time=2021-11-19, status=1, ipAttribution=)]

相关威廉亚洲官网

Eur Heart J:乳腺癌患者房颤的发生率、危险因素和死亡情况

女性确诊乳腺癌后AF发生率明显更高。诊断时较高的乳腺癌分期与较高的AF风险显著相关。在新的乳腺癌诊断中,新发AF会增加1年心血管死亡率,但不会增加与乳腺癌相关的死亡率。

Brit J Cancer:生命早期体重指数和乳腺癌、子宫内膜癌和卵巢癌风险的关系

对于生命早期肥胖,该研究的数据支持其与乳腺癌呈负相关,但与卵巢癌和子宫内膜癌风险呈正相关。

Cell子刊:癌症治疗专用代餐?可阻止三阴乳腺癌进展和癌症干细胞逃逸!

Cell Metab:模拟禁食饮食可以阻止三阴乳腺癌和癌症干细胞逃逸

BMJ:乳腺癌患者术后运动对上肢功能的影响

建议乳腺癌术后患者积极接受结构化运动干预,可有效降低上肢残疾风险

伤心总是难免的?乳腺癌放疗显著加速冠脉钙化进展!

Radiat Oncol:乳腺癌患者放疗后冠状动脉钙化负荷的加速:与年龄和种族匹配的健康女性的比较

Nature:华人团队发现最凶险乳腺癌的“帮凶”,打掉它就能攻入肿瘤内部

乳腺癌,是女性中最常见的癌症,而在2020年,乳腺癌取代肺癌,已成为全球第一大癌症,WHO国际癌症研究署(IARC)发布的2020年全球最新癌症负担数据显示,2020年全球乳腺癌新发病例高达226万例